Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2021-10-22 Investor Presentation
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation on the Financial Results" for the quarter and half year ended September 30, 2021. It contains detailed financial highlights, including revenue, EBITDA, PBT, PAT, segment revenue breakdowns, and operational metrics. The content is structured as a presentation with charts and tables summarizing financial performance and business updates. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or a brief summary. The presence of forward-looking statements and detailed segment information further supports that this is a presentation aimed at investors. Therefore, the document fits the definition of an Investor Presentation (IP).
2021-10-22 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 22, 2021, announcing the financial results of Gland Pharma Limited for the quarter and half year ended September 30, 2021. It contains detailed financial summary data including revenue, EBITDA, PAT, and market-wise revenue breakdown. It also discusses R&D expenses, capex, and mentions an upcoming earnings call to discuss the results. The document is not a full annual or interim report but a summary announcement of quarterly financial results with key highlights. It is not a transcript of the earnings call but references that the transcript will be uploaded later. The length is 9448 characters, which is consistent with a detailed earnings release. Therefore, the document fits the definition of an Earnings Release (ER). Q2 2022
2021-10-22 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Gland Pharma Limited dated October 22, 2021, reporting the outcome of a Board Meeting. It specifically mentions the approval of unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2021, along with the Limited Review Report. The document includes the auditor's review report pursuant to SEBI regulations, detailed financial data for the quarter and half year, and notes on accounting standards and subsidiary information. The presence of unaudited financial results and a limited review report for a quarterly period indicates this is an Interim / Quarterly Report. The document is substantive and contains actual financial statements and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-10-22 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Gland Pharma Limited dated October 22, 2021, reporting the outcome of a Board Meeting. It includes unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2021, along with a Limited Review Report by the auditors. The document references compliance with SEBI Listing Regulations and Indian Accounting Standards (Ind AS 34) for interim financial reporting. The presence of quarterly and half-year financial data, auditor's review report, and detailed financial tables indicates this is a comprehensive interim financial report rather than a brief earnings release or just an announcement. The document length (15,000 characters) and content confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2021-10-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal announcement addressed to stock exchanges regarding the receipt of US FDA tentative approval for a pharmaceutical product (Sugammadex Injection). It includes regulatory references (SEBI Listing Obligations and Disclosure Requirements Regulations), product details, and company background. The document is relatively short (3776 characters) and serves as a notification of a regulatory milestone rather than a detailed financial or operational report. There are no financial statements, earnings data, or management discussion. This fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and disclosures that do not fit other specific categories.
2021-10-08 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a notification addressed to stock exchanges about the allotment of equity shares following the exercise of Employee Stock Options (ESOP). It mentions the increase in issued share capital and is made pursuant to a regulatory requirement (SEBI Listing Obligations). The content is an announcement of a capital change event rather than a full report or detailed financial statement. The document length is short (1358 characters), and it does not contain financial statements or detailed analysis. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2021-10-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.